Clinical Trials Browser

Interventional × Has results × Bevacizumab × Clear all

NCT00217737 2026-03-18

Oxaliplatin, Leucovorin, and Fluorouracil With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for Stage II Colon Cancer

Phase 3 Active not recruiting

2,431 enrolled 13 charts

Gastrointestinal

Colonic Neoplasms

NCT00569127 2026-03-18

Octreotide Acetate and Recombinant Interferon Alfa-2b or Bevacizumab in Treating Patients With Metastatic or Locally Advanced, High-Risk Neuroendocrine Tumor

Phase 3 Active not recruiting

427 enrolled 17 charts

Neuroendocrine Tumors

NCT01167712 2026-03-18

Paclitaxel and Carboplatin With or Without Bevacizumab in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer

Phase 3 Active not recruiting

692 enrolled 11 charts

Brenner Tumor, Fallopian Tube Neoplasms

NCT02839707 2026-03-18

Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Phase 2/3 Active not recruiting

444 enrolled 17 charts

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT02971501 2026-03-17

Osimertinib With or Without Bevacizumab in Treating Patients With EGFR Positive Non-small Cell Lung Cancer and Brain Metastases

Phase 2 Active not recruiting

7 enrolled 9 charts

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT05116189 2026-03-09

KEYNOTE-B96

Phase 3 Active not recruiting

643 enrolled 17 charts 1 FDA

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT00433511 2026-03-03

Doxorubicin Hydrochloride, Cyclophosphamide, and Paclitaxel With or Without Bevacizumab in Treating Patients With Lymph Node-Positive or High-Risk, Lymph Node-Negative Breast Cancer

Phase 3 Active not recruiting

4,994 enrolled 11 charts

Breast Adenocarcinoma

NCT00588770 2026-03-03

Chemotherapy With or Without Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Phase 3 Active not recruiting

403 enrolled 10 charts

Lymphoid Interstitial Pneumonia, Squamous Cell Carcinoma of Head and Neck, Salivary Gland Neoplasms, Tongue Neoplasms

NCT04094688 2026-03-03

SOLARIS

Phase 3 Active not recruiting

455 enrolled 13 charts

Gastrointestinal

Colorectal Adenocarcinoma

NCT04068610 2026-03-02

COLUMBIA-1: Novel Oncology Therapies in Combination With Chemotherapy and Bevacizumab as First- Line Therapy in MSS-CRC

Phase 1/2 Active not recruiting

61 enrolled 35 charts

Gastrointestinal

Colonic Neoplasms

NCT01946529 2026-02-23

Therapeutic Trial for Patients With Ewing Sarcoma Family of Tumor and Desmoplastic Small Round Cell Tumors

Phase 2 Active not recruiting

24 enrolled 11 charts

Neuroectodermal Tumors, Primitive, Peripheral, Desmoplastic Small Round Cell Tumor

NCT02519348 2026-02-17

A Study of Durvalumab or Tremelimumab Monotherapy, or Durvalumab in Combination With Tremelimumab or Bevacizumab in Advanced Hepatocellular Carcinoma

Phase 2 Active not recruiting

433 enrolled 26 charts

Gastrointestinal

Carcinoma, Hepatocellular

NCT03133546 2026-02-06

BOOSTER

Phase 2 Completed

155 enrolled 23 charts

Non Small Cell Lung Cancer Metastatic

NCT03635567 2026-02-04

KEYNOTE-826

Phase 3 Completed

617 enrolled 29 charts 1 FDA

Parkinson Disease 4, Autosomal Dominant Lewy Body, Uterine Cervical Neoplasms

NCT02734004 2026-01-29

MEDIOLA

Phase 1/2 Active not recruiting

264 enrolled 32 charts

BreastGastrointestinalGynecologicThoracic

Breast Neoplasms, Ovarian Neoplasms, Stomach Neoplasms, Small Cell Lung Carcinoma

NCT00565851 2025-12-30

Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian, Epithelial, Primary Peritoneal, or Fallopian Tube Cancer

Phase 3 Active not recruiting

1,052 enrolled 27 charts

Brenner Tumor, Carcinoma, Adenocarcinoma, Mucinous, Fallopian Tube Neoplasms, Ovarian Neoplasms, Adenocarcinoma, Clear Cell

NCT01950390 2025-12-11

Ipilimumab With or Without Bevacizumab in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery

Phase 2 Completed

169 enrolled 14 charts

Melanoma

NCT01081262 2025-11-25

Carboplatin and Paclitaxel or Oxaliplatin and Capecitabine With or Without Bevacizumab as First-Line Therapy in Treating Patients With Newly Diagnosed Stage II-IV or Recurrent Stage I Epithelial Ovarian or Fallopian Tube Cancer

Phase 3 Active not recruiting

50 enrolled 13 charts

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT03307785 2025-11-25

Study of Niraparib, TSR-022, Bevacizumab, and Platinum-Based Doublet Chemotherapy in Combination With TSR-042

Phase 1 Completed

60 enrolled 91 charts

Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis, Neoplasms

NCT03193190 2025-11-21

A Study of Multiple Immunotherapy-Based Treatment Combinations in Participants With Metastatic Pancreatic Ductal Adenocarcinoma (Morpheus-Pancreatic Cancer)

Phase 1/2 Completed

341 enrolled 28 charts

Gastrointestinal

Pancreatic Adenocarcinoma

NCT03532295 2025-11-21

Retifanlimab and Epacadostat in Combination With Radiation and Bevacizumab in Patients With Recurrent Gliomas

Phase 2 Completed

51 enrolled 16 charts

Glioblastoma, Glioma

NCT02142803 2025-11-13

TORC1/2 Inhibitor MLN0128 and Bevacizumab in Treating Patients With Recurrent Glioblastoma or Advanced Solid Tumors

Phase 1 Active not recruiting

50 enrolled 16 charts

Fallopian Tube Neoplasms, Glioblastoma, Ovarian Neoplasms

NCT03280563 2025-11-10

MORPHEUS HR+BC

Phase 1/2 Completed

144 enrolled 25 charts

Breast Neoplasms

NCT01191697 2025-11-03

CAPOX, Bevacizumab and Trastuzumab for Patients With HER2-Positive Metastatic Esophagogastric Cancer

Phase 2 Completed

37 enrolled 11 charts

Gastrointestinal

Esophageal Neoplasms, Stomach Neoplasms

NCT03740165 2025-10-22

KEYLYNK-001

Phase 3 Active not recruiting

1,367 enrolled 29 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body, Fallopian Tube Neoplasms, Ovarian Neoplasms, Peritoneal Neoplasms

NCT04008030 2025-10-03

CheckMate 8HW

Phase 3 Active not recruiting

839 enrolled 22 charts 1 FDA

Gastrointestinal

Colorectal Neoplasms

NCT05446870 2025-10-01

MK-4830-002

Phase 2 Completed

160 enrolled 19 charts

Ovarian Neoplasms

NCT00861705 2025-09-30

Paclitaxel With or Without Carboplatin and/or Bevacizumab Followed by Doxorubicin and Cyclophosphamide in Treating Patients With Breast Cancer That Can Be Removed by Surgery

Phase 2 Completed

454 enrolled 23 charts

Breast Neoplasms, Breast Neoplasms, Male, Triple Negative Breast Neoplasms

NCT04487067 2025-09-22

AMETHISTA

Phase 3 Completed

152 enrolled 16 charts

Gastrointestinal

Carcinoma, Hepatocellular

NCT05678257 2025-09-12

A Study of NUC-3373 in Combination With Other Agents in Patients With Colorectal Cancer

Phase 2 Terminated

180 enrolled 16 charts

Gastrointestinal

Colonic Neoplasms, Neoplasm Metastasis, Neoplasms, Colorectal Neoplasms

NCT00334815 2025-08-24

Combination Chemotherapy, Radiation Therapy, and Bevacizumab in Treating Patients With Newly Diagnosed Stage III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery

Phase 2 Active not recruiting

29 enrolled 10 charts

Adenocarcinoma of Lung, Adenocarcinoma, Bronchiolo-Alveolar

NCT02681549 2025-08-07

Pembrolizumab Plus Bevacizumab for Treatment of Brain Metastases in Metastatic Melanoma or Non-small Cell Lung Cancer (NSCLC)

Phase 2 Completed

41 enrolled 20 charts

CNSDermatologicThoracic

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung, Melanoma

NCT01295944 2025-08-05

Carboplatin and Bevacizumab for Recurrent Ependymoma

Phase 2 Completed

35 enrolled 17 charts

Brain Neoplasms, Ependymoma, Neoplasms, Neurologic Manifestations, Spinal Cord Neoplasms

NCT03326193 2025-07-31

A Study of Niraparib Combined With Bevacizumab Maintenance Treatment in Participants With Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy

Phase 2 Completed

105 enrolled 29 charts

Ovarian Neoplasms

NCT03574779 2025-07-15

OPAL

Phase 2 Completed

77 enrolled 8 charts

Ovarian Neoplasms

NCT05330429 2025-07-01

ELEVATE CRC

Phase 2 Terminated

77 enrolled 22 charts

Gastrointestinal

Colorectal Neoplasms

NCT03694262 2025-05-30

EndoBARR

Phase 2 Active not recruiting

30 enrolled 7 charts

Endometrial Neoplasms

NCT00601900 2025-05-23

Tamoxifen Citrate or Letrozole With or Without Bevacizumab in Treating Women With Stage IIIB or Stage IV Breast Cancer

Phase 3 Completed

394 enrolled 11 charts

Breast Neoplasms

NCT02138617 2025-05-18

Genotype-Directed Study Of Irinotecan Dosing In FOLFIRI + BevacizumabTreated Metastatic Colorectal Cancer

Phase 2 Completed

100 enrolled 13 charts

Gastrointestinal

Colonic Neoplasms

NCT04732286 2025-05-08

A Study of Atezolizumab in Combination With Bevacizumab in Spanish Patients With Unresectable or Unsuitable for Locoregional Treatments Hepatocellular Carcinoma Not Previously Treated With Systemic Therapy

Phase 3 Terminated

100 enrolled 18 charts

Gastrointestinal

Carcinoma, Hepatocellular

NCT03428958 2025-04-23

A Safety, Pharmacokinetic and Efficacy Study of NUC-3373 in Combination With Standard Agents Used in Colorectal Cancer Treatment

Phase 1/2 Completed

111 enrolled 22 charts

Gastrointestinal

Colonic Neoplasms, Colorectal Neoplasms

NCT04512430 2025-04-02

Neo-DIANA: Neoadjuvant Treatment for EGFR Mutated Patients

Phase 2 Terminated

4 enrolled 9 charts

Bronchial Neoplasms, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, Lung Diseases, Lung Neoplasms, Respiratory Tract Neoplasms, Thoracic Neoplasms

NCT00513786 2025-03-28

Evaluation of Carboplatin/Paclitaxel/Bevacizumab in the Treatment of Advanced Stage Endometrial Carcinoma

Phase 2 Completed

38 enrolled 12 charts

Endometrial Neoplasms

NCT00520975 2025-03-28

Bevacizumab in Treating Patients With Metastatic Breast Cancer That Overexpresses HER-2/NEU

Phase 3 Terminated

96 enrolled 16 charts

Breast Neoplasms

NCT03024437 2025-03-20

Atezolizumab in Combination With Entinostat and Bevacizumab in Patients With Advanced Renal Cell Carcinoma

Phase 1/2 Terminated

31 enrolled 19 charts

Kidney Neoplasms, Neoplasm Metastasis

NCT03676192 2025-03-17

To Compare Efficacy and Safety of CT-P16 and European Union-Approved Avastin as First-Line Treatment for Metastatic or Recurrent Non-Squamous Non-Small Cell Lung Cancer

Phase 3 Completed

689 enrolled 18 charts

Adenocarcinoma of Lung

NCT03829410 2025-03-04

Onvansertib in Combination With FOLFIRI and Bevacizumab for Second Line Treatment of Metastatic Colorectal Cancer Patients With a KRAS Mutation

Phase 1/2 Completed

68 enrolled 21 charts

Gastrointestinal

Colorectal Neoplasms

NCT00324805 2025-03-03

Chemotherapy With or Without Bevacizumab in Treating Patients With Stage IB, Stage II, or Stage IIIA Non-small Cell Lung Cancer That Was Removed By Surgery

Phase 3 Completed

1,501 enrolled 16 charts

Carcinoma, Non-Small-Cell Lung

NCT03396926 2025-02-28

Pembrolizumab, Capecitabine, and Bevacizumab for Treating Colorectal Cancer

Phase 2 Completed

44 enrolled 15 charts

Gastrointestinal

Colorectal Neoplasms

NCT03452579 2025-02-28

Nivolumab Plus Standard Dose Bevacizumab Versus Nivolumab Plus Low Dose Bevacizumab in GBM

Phase 2 Active not recruiting

90 enrolled 16 charts

Glioblastoma